Redwood City Newswire

Redwood City Newswire

Comprehensive Real-Time News Feed for Redwood City, CA.

Results 1 - 20 of 32 for "u:biospace.com" in Redwood City, CA

  1. Why This Bay Area Heart Software Biotech Could Become Silicon Valley's Newest UnicornRead the original story w/Photo

    Thursday Nov 30 | BioSpace

    Redwood City-based medical software startup HeartFlow is on the hunt for a $150 million Series E round of funding, which would push the company's private valuation above $1 billion, according to a new regulatory filing first spotted by PitchBook.

    Comment?

  2. Mallinckrodt Pays $117M for This Bay Area Biotech and It's Failed Liver DrugRead the original story w/Photo

    Nov 1, 2017 | BioSpace

    Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right -- -- Hepatic encephalopathy is a neuropsychiatric syndrome associated with hyperammonemia that occurs as complications of liver disease, such as cirrhosis -- -- Roughly 200,000 U.S. hospitalizations result from acute HE each year; approximately 1.5 to 2 million patients are at risk of recurrent HE -- -- Average of $30,000-$60,000 per hospital stay; total acute and recurrent HE market potential opportunity of $5.0-$7.0 billion -- -- If approved, OCR-002 is expected to become the first intravenous pharmacologic option indicated for treatment of acute HE in the U.S.; FDA Orphan Drug designation and Fast Track status granted; EMA Orphan Drug designation -- -- Acquisition further expands Mallinckrodt's focus on treatments for severe and critical diseases in hepatic and ... (more)

    Comment?

  3. Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver DrugRead the original story w/Photo

    Nov 1, 2017 | BioSpace

    Staines-Upon-Thames, UK-based Mallinckrodt has agreed to buy Redwood City, Calif.,-based Ocera Therapeutics in a deal that could hit $117 million. Ocera is a clinical-stage biopharma company that focuses on orphan diseases and serious liver diseases.

    Comment?

  4. Investors May be Overlooking This Small, Fast-Growing Bay Area BiotechRead the original story w/Photo

    Oct 24, 2017 | BioSpace

    You've probably heard those advertisements for "the power of protein," referring to the addition of enzymes to detergent. Enzymes are used in plenty of commercial products, as well as us in industrial manufacturing processes.

    Comment?

  5. Codexis, Inc. And Enter Into Healthcare-Focused Protein Engineering Platform PartnershipRead the original story

    Oct 11, 2017 | BioSpace

    Includes an option for the global development of CDX-6114 for PKU, marking Codexis' first partnership for an internally developed biotherapeutic product.

    Comment?

  6. Codexis, Inc. And Enter Into Healthcare-Focused Protein Engineering Platform PartnershipRead the original story

    Oct 11, 2017 | BioSpace

    Includes an option for the global development of CDX-6114 for PKU, marking Codexis' first partnership for an internally developed biotherapeutic product.

    Comment?

  7. Revolution Medicines Appoints M.D. To Board Of DirectorsRead the original story

    Oct 5, 2017 | BioSpace

    REDWOOD CITY, Calif.-- -- REVOLUTION Medicines, Inc. , a drug discovery and development company focused on frontier cancer targets, today announced the appointment of Vincent Miller, M.D., to its board of directors. Dr. Miller is a leader in precision oncology enabled by genomic testing and expert in lung cancer, and he will continue to serve as chief medical officer of Foundation Medicine.

    Comment?

  8. New Data Show Karius Test Improves Pathogen Detection In Challenging Patient PopulationsRead the original story

    Oct 3, 2017 | BioSpace

    SEQ Trial Demonstrates the Karius Test's Ability to Rapidly Identify a Broad Range of Pathogens in Septic Patients With a Single Blood Draw - REDWOOD CITY, Calif. & SAN DIEGO-- --Karius, Inc., a life sciences company focused on conquering infectious diseases, today announced several presentations that demonstrate the ability of the Karius Digital CultureTM Test to rapidly and accurately identify pathogens in patients with sepsis, bloodstream infections, neutropenic fever, who are immunocompromised, or have rare infections such as Mycobacterium chimaera .

    Comment?

  9. Soleno Therapeutics Provides Corporate Update And Reports Second Quarter 2017 Financial ResultsRead the original story

    Aug 13, 2017 | BioSpace

    REDWOOD CITY, Calif., Aug. 11, 2017 -- Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the three and six months ended June 30, 2017. "Following our recent successful meeting with the FDA, we expect to initiate a Phase III clinical trial of DCCR in Prader-Willi Syndrome by the end of the year," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics.

    Comment?

  10. Avinger Announces Second Quarter 2017 ResultsRead the original story

    Aug 8, 2017 | BioSpace

    REDWOOD CITY, Calif., Aug. 08, 2017 -- Avinger, Inc. , a leading developer of innovative treatments for peripheral artery disease , today reported results for the second quarter ended June 30, 2017.

    Comment?

  11. Nevro Reports Second Quarter 2017 Financial ResultsRead the original story

    Aug 7, 2017 | BioSpace

    REDWOOD CITY, Calif., Aug. 7, 2017 /PRNewswire/ -- Nevro Corp. , a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and six months ended June 30, 2017.

    Comment?

  12. Relypsa Announces European Approval Of Veltassa To Treat Adult...Read the original story

    Jul 20, 2017 | BioSpace

    Today's European Commission approval is the second worldwide; in the U.S., more than 33,000 patients have been treated with Veltassa since it was approved by the FDA in 2015 Patients with advanced chronic kidney disease and/or heart failure are especially susceptible to hyperkalemia, which, if untreated, can lead to abnormal heart rhythms and even sudden death REDWOOD CITY, Calif., July 21, 2017 -- Relypsa, Inc., a Vifor Pharma Group company, today announced that the European Commission has approved the Marketing Authorization Application for VeltassaA for the treatment of hyperkalemia, or elevated blood potassium levels.

    Comment?

  13. Biotricity Provides Mid-Year Update For ShareholdersRead the original story

    Jun 5, 2017 | BioSpace

    REDWOOD CITY, Calif., June 06, 2017 -- Biotricity, Inc. , a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, has had a strong start to 2017 with a number of key developments. Some recent highlights include considerable progress towards commercializing Biotricity's remote patient monitoring solution, Bioflux , through a new relationship with a contract manufacturer for mass production, and filing for its final FDA 510 .

    Comment?

  14. Karius Test Demonstrates Ability To Detect Pathogens From Cell-Free...Read the original story

    Jun 4, 2017 | BioSpace

    REDWOOD CITY, Calif. & NEW ORLEANS-- --Karius, Inc., a life sciences company focused on conquering infectious diseases, today announced new data from four studies presented at the American Society for Microbiology's Microbe 2017 conference in New Orleans.

    Comment?

  15. Pulmonx, Inc. Release: New Data From Two Multi-Center Randomized...Read the original story

    May 23, 2017 | BioSpace

    WASHINGTON & REDWOOD CITY, Calif.-- -- Pulmonx A , Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the ZephyrA Endobronchial Valve in emphysema patients without collateral ventilation. Six-month data from both the TRANSFORM and IMPACT trials, presented this week at the American Thoracic Society international conference, demonstrate that Zephyr valves provide positive benefits in these patients with either homogeneous or heterogeneous distribution of emphysema.

    Comment?

  16. Otsuka Pharma And Proteus Digital Health Resubmit Application To FDA For First Digital MedicineRead the original story

    May 22, 2017 | BioSpace

    Potential new Digital Medicine consists of Otsuka's ABILIFY A embedded with the Proteus ingestible sensor, for serious mental illness Drug/device product digitally records medication ingestion and, with patient consent, shares information with patient's healthcare providers and selected family and friends If approved by the FDA, Digital Medicine would provide patients and physicians with an objective, personalized measure of medication adherence and activity level, as well as self-reported rest and mood 1 TOKYO & REDWOOD CITY, Calif.-- --Otsuka Pharmaceutical Co., Ltd. and Proteus Digital HealthA today announce that the United States Food and Drug Administration has acknowledged receipt of the New Drug Application resubmission for the drug-device combination product of ABILIFYA embedded with a Proteus ingestible sensor in a single tablet.

    Comment?

  17. University Of Denver Libraries Select Yewno Discover Research ApplicationRead the original story

    May 18, 2017 | BioSpace

    Yewno, Inc., announced today that The University of Denver Libraries have selected the Yewno Discover research application to support the explorative and interdisciplinary search needs of its campus. "We are excited to be entering a new phase in Yewno's journey.

    Comment?

  18. Coherus Prevails In ???135 IPR DecisionRead the original story

    May 16, 2017 | BioSpace

    Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135 REDWOOD CITY, Calif., May 16, 2017 -- Coherus BioSciences, Inc. , today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office ruled in favor of Coherus' petitions for Inter Partes Review of AbbVie's U.S. Patent 8,889,135 . The PTAB's decision invalidates all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRAA subcutaneously every 13 to 15 days.

    Comment?

  19. Ocera Therapeutics Reports First Quarter 2017 Financial Results And Provides Clinical UpdateRead the original story

    May 9, 2017 | BioSpace

    REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 09, 2017 -- Ocera Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ended March 31, 2017 and provided updates on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy , a debilitating liver disorder and significant burden on the healthcare system.

    Comment?

  20. Catastrophic Year for Bay Area's OncoMed Continues as Lead Drug Comes ...Read the original story

    May 7, 2017 | BioSpace

    REDWOOD CITY, Calif., May 08, 2017 -- OncoMed Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced first quarter financial results. As of March 31, 2017, cash, and short-term investments totaled $156.9 million.

    Comment?

Redwood City Job Listings
View or post Redwood City job listings on Topix.
Redwood City Real Estate
News, listings, and foreclosures in Redwood City from Topix.
Redwood City Mortgages
Find mortgage rates in Redwood City on Topix.